Akorn and Natco in API supply sharing deal

30 April 2006

US firm Akorn says that it has signed an active pharmaceutical ingredients supply and margin sharing agreement with Natco Pharma, located in Hyderabad, India, to commercialize two Abbreviated New Drug Application-injectable drug products.

The two ANDA drug products will focus on the anti-emetic and cancer related markets, and have a combined current market size of around $875.0 million. Under the deal, Natco will be responsible for the supply of APIs for both products, while Akorn will be responsible for the manufacturing, regulatory submissions, marketing and distribution in the hospital, clinic, and home health care markets in the USA and Canada.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight